Pediatrix Q2 EPS $0.46, Adjusted $0.53; raises FY 2025 EBITDA guidance to $245-255M

Pediatrix Medical Group, Inc.

2025-Q2 EPS reported $0.70 revenue$927,203,000

Net revenue $469M; net income $39M vs. loss of $153M a year ago due to non-cash impairment.
Adjusted EBITDA $73M, up from $58M in Q2 2024; raised FY guidance to $245-255M (from $220-240M).
Same-unit revenue +6.4% with neonatology NICU days up 6.0% year-over-year.
Cash from continuing operations $138M; total debt $606M; no revolver borrowings.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.